Rock Health April 8, 2024
Adriana Krasniansky, Mihir Somaiya

Q1 2024 moved us from times of transition to full entrenchment in a new digital health funding cycle. The quarter’s $2.7B across 133 digital health demonstrated higher deal volume at lower check sizes. In the private markets, creative financing measures were the name of the game, while AI drove investment energy and attention refocused on startups’ abilities to demonstrate outcomes. In the public markets, stock delistings continued to change the makeup of digital health’s publicly-traded cohort, impacting how digital health players and investors think about exit potential.

Expectations are resetting for digital health players both private and public, pushing them to align to different paradigms of success (strong outcomes and healthy margins instead of high projected growth rates) and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Investments, Mergers & Acquisitions / JV, Survey / Study, Technology, Trends
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
Digital health funding declines, but check sizes swell: CB Insights
Hummingbird Healthcare Raises $10M to Address Persistent Barriers to Patient Access
General Catalyst, Summa Health deal to close by end of 2024
Q Bio Secures $27M to Expand Full-Body MRI with Mark I Scanner

Share This Article